Clinical Trial Update: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing Cerebraca Wafer plus Temozolomide vs Temozolomide alone in recurrent glioblastoma with IDH-wildtype, across Phase 2 and Phase 3,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• Cerebraca Wafer
• Temozolomide (Temozolomide)

Snippet

Sponsor: Everfront Biotech Co., Ltd. | Conditions: Recurrent Glioblastoma, IDH-Wildtype | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING